SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes [Seeking Alpha]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Seeking Alpha
SAB-142 may preserve beta-cell function and C-peptide with a cleaner safety profile than animal-derived immune therapies, supporting potential repeat dosing. The registrational Phase 2b SAFEGUARD study is the key value driver, while broader autoimmune programs provide secondary optionality. SAB Biotherapeutics appears well-capitalized after its recent raise, which materially strengthens its runway and reduces any near-term dilution risks. I think the stock offers speculative upside, but investors must accept binary clinical risk, thin trading liquidity, and a long-term investment horizon. Fuse Img/iStock via Getty Images SAB Biotherapeutics, Inc. ( SABS ) is a biopharmaceutical company that develops SAB-142, a potential disease-modifying therapy for immune and autoimmune conditions. Currently, the candidate is being studied for the treatment of Type 1 Diabetes (T1D), which is when the
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 [Yahoo! Finance]Yahoo! Finance
- SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 [Yahoo! Finance]Yahoo! Finance
- SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026GlobeNewswire
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressGlobeNewswire
- SAB Biotherapeutics (SABS) had its "sell (d+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SABS
Sec Filings
- 4/22/26 - Form 8-K
- 3/31/26 - Form S-8
- 3/25/26 - Form 4
- SABS's page on the SEC website